TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00789581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2
Study: NCT03061838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera®
Description: 1000 mg intravenously
Study: NCT00789581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2
Study: NCT03441490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided-ICBT with learning support
Description: Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through mail, 8 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided-ICBT with learning support and chat
Description: Internet-based cognitive behavioural therapy with learning support and therapeutic guidance through chat, 8 weeks.
Study: NCT03459105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% heavy bupivacaine
Description: 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
Study: NCT01234337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capecitabine was administered orally at a dose of 1,000 mg/m\^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m\^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m\^2 twice daily,
Study: NCT01579526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP01
Description: comparison of different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01
Description: comparison of different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01
Description: comparison of different dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01
Description: comparison of different dosages
Study: NCT01030757

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy treatment
Description: * A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days~* Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours~* Dose will be prescribed to the isodose line which covers at least 90% of the PTV~* Dose homogeneity +/- 5%
Study: NCT02180464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41004
Study: NCT03061838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritumax®
Description: 1000 mg intravenously
Study: NCT00338689

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lower protein formula; Higher protein formula
Description: During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lower protein formula; Higher protein formula
Description: During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
Study: NCT03316131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad
Description: Randomized patients will receive orally once daily fixed dose of verinurad in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
Study: NCT02180464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAS41004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control
Study: NCT01289600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical ventilation
Description: The mechanical ventilator is set to different ventilation modes as described in the individual arms.
Study: NCT00396344

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Çontrol
Description: Intravenous saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intravenous stress dose of hydrocortisone
Study: NCT00396344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intravenous pharmacologic hydrocortisone
Study: NCT00789581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2
Study: NCT01131546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine besylate
Description: Once daily, 7AM - 10AM
Study: NCT03316131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dapagliflozin matched placebo
Description: Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: verinurad + febuxostat + dapagliflozin; Treatment B: verinurad + febuxostat + placebo
Study: NCT04449614

Intervention type: PROCEDURE
Intervention: Thoracoscopic CPAM resection
Description: Surgical removal of lung lesion
Study: NCT06135558

Intervention type: DIAGNOSTIC_TEST
Intervention: MAI detection
Description: to detect the presence of marginal acute inflammation

Intervention type: DIAGNOSTIC_TEST
Intervention: MAI detection
Description: to detect the presence of marginal acute inflammation
Study: NCT01117493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expert Patient Programme
Description: Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
Study: NCT00353561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boric
Description: Gelatin capsules filled with 600 mg of boric acid

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: 150 mg oral fluconazole gives once in 14 days
Study: NCT01131546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine besylate
Description: Once daily, 7AM - 10AM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine maleate
Description: Once daily, 7AM - 10AM
Study: NCT01117493

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual care
Description: Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
Study: NCT03174379

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care with no acupuncture
Description: The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
Study: NCT00615368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Description: 1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl (Placebo)
Description: 1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
Study: NCT01529944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
Study: NCT04038190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral activation
Description: Behavioral activation (BA) is an intervention that indirectly addresses psychopathy by guiding individuals to identify goals in their lives, and encouraging individuals to engage in reinforcing activities that align with their goals (Lejuez et al, 2001). While initially used to treat depression, BA has been efficaciously applied to substance use because BA acts on the same reinforcement system common to many disorders (Daughters et al., 2018).
Study: NCT01404000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodinated Active Charcoal (IodoCarb)
Description: 3 g will be given as an oral suspension once daily for 56 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iodinated Active Charcoal (IodoCarb)
Description: 3 g will be given as an oral suspension once daily for 56 days
Study: NCT03765385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity training
Description: Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: Sessions will be performed twice weekly for 12 weeks, in groups of 8-10 participants and two supervisors.
Study: NCT03174379

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
Study: NCT02171780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01337752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHQ880

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BHQ880 Placebo
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bortezomib
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: Oral
Study: NCT01517503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-55 minute sessions will be provided, with sessions generally held weekly for the first 8 sessions and once every two weeks for the next 8 sessions.
Study: NCT01453959

Intervention type: DRUG
Group type: OTHER
Intervention: Fludrocortisone
Description: Fludrocortisone in a dose of 0.4 mg/day for 7 days

Intervention type: OTHER
Group type: OTHER
Intervention: Diet cycles
Description: Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
Study: NCT06135558

Intervention type: DIAGNOSTIC_TEST
Intervention: MAI detection
Description: to detect the presence of marginal acute inflammation
Study: NCT00663533

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Vas-X
Description: mechanical vasectomy device
Study: NCT02073227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR, 500 mg
Description: Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
Study: NCT03260998

Intervention type: DIAGNOSTIC_TEST
Intervention: electrocardiogram
Description: measurment of QT dispersion and corrected QT and other electrocardiogram changes

Intervention type: DIAGNOSTIC_TEST
Intervention: electrocardiogram
Description: measurment of QT dispersion and corrected QT and other electrocardiogram changes
Study: NCT02269852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent seasonal influenza vaccine
Description: * Infants: 0.25 ml/ dose;~* Adults: 0.5 ml/ dose;~* Seniors: 0.5 ml/ dose;
Study: NCT02073227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg
Description: Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Description: Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
Study: NCT05140486

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation: shortwave diathermy and perceptual training
Description: All subjects in the rehabilitation group received shortwave diathermy therapy 5 days per week for 4 weeks and perceptual training 5 days per week for 10 weeks.
Study: NCT04102410

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sprints
Description: Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprints
Description: Two sprints of 8 seconds on a cycle ergometer will be performed for determine Force/Velocity Profile (FVP).~Realized at inclusion and 2 months after.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Vertical jumps
Description: Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vertical jumps
Description: Two vertical jumps will be performed. Height of theses vertical jumps will be measured by application My jump 2 to determine muscle power.~Realized at inclusion and 2 months after.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionary Short Form-12 (SF-12)
Description: Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionary Short Form-12 (SF-12)
Description: Questionary Short Form-12 (SF-12) will be performed to evaluate quality of life. It is composed of 12 questions.~Realized at inclusion and 2 months after.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: activity actigraph
Description: Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: activity actigraph
Description: Activity actigraph will be wearing by patient during 7 consecutive days. It measures the level of physical activity and the sedentary lifestyle of patients.~Realized at inclusion and 2 months after.
Study: NCT01549444

Intervention type: OTHER
Intervention: presence of maternal risk factor for hypertension
Study: NCT05212649

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.

Intervention type: DIAGNOSTIC_TEST
Intervention: cardiopulmonary exercise test
Description: CPET was performed in this HF cohort within one month after being discharged and interpreted as previously described. Patients underwent an upright graded cycle ergometer exercise using a personalized ramp protocol or a motorized treadmill using a modified Bruce or Cornell protocol. Peak VO2 data measured by cycle ergometer were increased by 10% to allow a comparison between the two different procedures. Peak VO2 was defined as the highest 30-second average value obtained during exercise. Submaximal CPET variables such as ventilatory efficiency were calculated by the slope of VE versus VCO2 below the ventilatory compensatory point (VCP). If the slope of VE/VCO2 can't be calculated, we used the nadir of VE/VCO2, or the ratio of VE/VCO2 at the anaerobic threshold (AT) as the variable of ventilatory efficiency. The AT was determined by the V-slope method.
Study: NCT03654651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut
Description: Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.
Study: NCT04102410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Program composed of two 2 training strategies
Description: Program composed of two 2 training strategies according to the initial Force/Velocity Profile (FVP) will be realized at the inclusion.~There are :~* Strategy experimental-speed: speed training strategy for subjects with a force-speed profile (PFV) in favour of force~* Strategy experimental-force: force training strategy for subjects with a force-speed profile (PFV) in favour of speed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Program of usual practice
Description: Program composed of training in force and speed independently of the initial Force/Velocity Profile (FVP).
Study: NCT03672045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: carbetocin administered IV, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: carbetocin administered IV, over 1 minute following delivery of the fetal head

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: carbetocin administered IV, over 1 minute following delivery of the fetal head
Study: NCT00789581

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone (Ixempra)
Description: Ixabepilone 40 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (Taxol)
Description: Paclitaxel 80 mg/m2